Immune BCG Market to Reach $735 Million in 2035, Growing at 5.1% CAGR

Immune BCG market valued at $450.3 million in 2025 and is projected to reach $735 million by 2035, growing at a CAGR of 5.1% during the forecast period (2026-2035). The market comprises Bacillus Calmette–Guérin (BCG) vaccines and immunotherapies used primarily for tuberculosis prevention and bladder cancer treatment. The market is witnessing steady global growth driven by the continued burden of tuberculosis and the expanding use of BCG in oncology, particularly for non-muscle invasive bladder cancer treatment. Growth is further supported by national immunization programs, increasing awareness regarding early disease prevention, and rising healthcare access in emerging economies. Pharmaceutical manufacturers are focusing on improving production capacity, ensuring supply chain stability, and enhancing formulation quality to address periodic global shortages. Additionally, ongoing research into BCG’s immunomodulatory effects and potential applications in broader infectious and autoimmune diseases is contributing to long-term market expansion. According to global health agencies, the widespread implementation of immunization initiatives and disease monitoring programs has significantly strengthened demand forecasting and distribution of BCG vaccines worldwide. Public health databases and surveillance systems play a crucial role in estimating vaccine coverage, disease prevalence, and long-term immunization needs across regions.

Browse the full report description of “Immune BCG Market Size, Share & Trends Analysis Report by Type (0.5ml Package, 1ml Package, 2ml Package, and Others), By Application (Hospitals and Clinics) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/immune-bcg-market

Key Statistics: Immune BCG at a Glance

• Tuberculosis remains one of the top infectious killers globally, with over 10 million new cases reported annually, sustaining strong demand for BCG vaccination.
• More than 100 countries include BCG vaccination in their national immunization programs, particularly targeting newborns and children.
• BCG therapy is used in over 70% of non-muscle invasive bladder cancer cases as a standard immunotherapy, reinforcing its clinical importance beyond vaccination.

Key Innovators Driving Immune BCG Transformation

The key players in the Immune BCG market include China National Pharmaceutical Group Corporation, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi S.A, among others.

• In June 2025, Serum Institute of India Pvt. Ltd. expanded its production capacity for BCG vaccines to support global demand and improve supply consistency across developing regions.
• In April 2025, Merck & Co., Inc. strengthened its oncology portfolio by optimizing distribution strategies for BCG-based immunotherapy used in bladder cancer treatment to improve accessibility for healthcare providers.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - China National Pharmaceutical Group Corporation, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi S.A, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Immune BCG Market Report Segment

By Type

• 5ml Package
• 1ml Package
• 2ml Package
• Others

By Application

• Hospital
• Clinic

Global Immune BCG Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immune-bcg-market